Esperion: Drug Recall
Recall #D-1143-2023 · 08/16/2023
Class III: Low Risk
Recall Details
- Recall Number
- D-1143-2023
- Classification
- Class III
- Product Type
- Drug
- Recalling Firm
- Esperion
- Status
- Completed
- Date Initiated
- 08/16/2023
- Location
- Ann Arbor, MI, United States
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 45,240 bottles
Reason for Recall
Failed dissolution specifications: below specification results at stability 12-month
Product Description
Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, 30 tablets, Rx only, Manufactured for: Esperion Therapeutics, Inc, Ann Arbor, MI 48108, NDC 72426-818-03
Distribution Pattern
Nationwide USA
Other Recalls by Esperion
- Class III: Low Risk 03/27/2024
Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.